IASLC 2024 World Conference on Lung Cancer
September 7 – 10, 2024
San Diego, CA
BOOTH #408
Connect with Caris Life Sciences at IASLC WCLC
Join Caris Life Sciences at the IASLC World Conference on Lung Cancer (WCLC) in San Diego, CA. Visit us at booth #408 to uncover the latest breakthroughs in precision medicine and discover how our products and services are leading the molecular revolution. Whether you are treating patients in the clinic or building the next wave of therapeutics, be sure to stop by and learn how Caris can support your precision medicine program.
- Comprehensive molecular profiling – no matter the specimen type, tissue or blood:
- Tissue: DNA, RNA and Protein biomarker analysis
- Blood: Caris Assure™ featuring somatic tumor, clonal hematopoiesis and incidental germline* characterization
- Whole exome and whole transcriptome sequencing for every patient
- 23,000 genes via Whole Exome Sequencing (WES – DNA)
- 61,000 transcripts via Whole Transcriptome Sequencing (WTS – RNA)
Presentations and Posters
Caris and its collaborators from leading cancer centers, including those within the Precision Oncology Alliance™ (POA), will collectively present five studies during WCLC.
POSTER PRESENTATIONS:
- Association of NEDD9 expression and survival of patients with KRAS mutant and STK11 mutant non-small cell lung cancer (KRASMUT/STK11MUT-NSCLC).
(Abstract Number: P1.06B.07) Sunday, September 8; 12:00-2:00 PM PDT - HER3 expression across genomic subsets of NSCLC.
(Abstract Number: P1.06B.16) Sunday, September 8; 12:00-2:00 PM PDT - SEZ6 expression in neuroendocrine tumors.
(Abstract Number: P3.13D.11) Monday, September 9; 12:00-2:00 PM PDT - First-line treatments for advanced pure large cell neuroendocrine tumors (LCNEC): Insights from a global clinico-genomic study.
(Abstract Number: P3.13C.09) Monday, September 9; 12:00-2:00 PM PDT - Evaluation of the immune landscape of patients with adenosquamous NSCLC (LUAS).
(Abstract Number: P3.06E.01) Monday, September 9; 12:00-2:00 PM PDT
Caris Abstracts and Presentation Schedule
Caris’ strong presence at WCLC 2024 demonstrates the clinical value of comprehensive molecular profiling and our commitment to transforming lives through research. Download the abstracts and presentation schedule, including a complete list of summaries highlighting the research presented at WCLC 2024.
Certain products and features may vary based on region or territory.
*Not a replacement for comprehensive germline testing. Incidental pathogenic alterations detected in ACMG recognized cancer genes are reported. Negative results do not imply the patient does not harbor a germline mutation.